Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer

Exclusion Criteria

• •Any prior systemic therapy for NSCLC
• •Major surgical procedure or other investigational agents within 4 weeks before study enrollment
• •Need for concomitant use of other thiazolidinediones during the study
• •History of any of the following conditions within 6 months prior to initiating study treatment: Diabetes mellitus requiring treatment with insulin or sulfonylureas or thiazolidinediones (TZDs) agents; Myocardia infarction with significant impairment of cardia function; Malabsorption syndrome, chronic diarrhea, inflammatory bowel disease or partial bowel obstruction;
• •Clinically active brain metastases, uncontrolled seizure disorder; spinal cord compression or carcinomatous meningitis